Mobile website
Prompt Report
SELDI-TOF-MS technology in screening for biomarkers of trastuzumab resistance in breast cancer patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To compare the serum protein mass spectra between trastuzumab resistant and non-resistant breast cancer patients by SELDI-TOF-MS (surface enhanced laser desorption/ionization-time of flight-mass spectrometry), so as to screen for biomarkers of trastuzumab resistance. Methods: Thirty-five breast cancer patients undergoing trastuzumab therapy in Fujian Tumor Hospital from Jan. 2008 to Oct. 2009 were included in this study. They included 11 trastuzumab resistant patients and 24 non-resistant patients according to clinical trastuzumab resistance standard. Serum protein mass spectrum difference between trastuzumab resistance and non-resistant patients was detected by SELDI-TOF-MS, and a protein peak ratio of 1.5 was used as SELDI-TOF-MS trastuzumab resistance standard. We analyzed the sensibility, specificity, positive and negative predictive values of the SELDI-TOF-MS trastuzumab resistance standard. Results: Trastuzumab resistance assessed by clinical trastuzumab resistance standard was not correlated with ages, clinical stages, lymph node metastases and double-negative expression of ER/PR in breast cancer patients. The expression of serum protein peaks 7 971 Da, 9 284 Da in trastuzumab resistant patients were significantly decreased (P<0.05) by comparing the serum proteomic mass spectra of trastuzumab resistant and non-resistant patients. We then used SELDI-TOF-MS trastuzumab resistant definition to judge trastuzumab resistant and non-resistant patients; the sensibility was 81.82% (9/11), specificity was 83.33% (20/24), positive predictive value was 69.23% (9/13), and negative predictive value was 9091% (20/22) when peak 7 971 Da was used; and the sensibility was 72.73% (8/11), specificity was 79.17% (19/24), positive predictive value was 61.54% (8/13) and negative predictive value was 86.36% (19/22) when peak 9 284 Da was used. Conclusions: Examination of serum protein peaks 7 971 Da and 9 284 Da expression by SELDI-TOF-MS technology in breast cancer patients may be used for predicting trastuzumab resistance.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Fujian Province（No. 2007J0263）
Clc Number:
